These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Target-Specific Prediction of Ligand Affinity with Structure-Based Interaction Fingerprints. Leidner F; Kurt Yilmaz N; Schiffer CA J Chem Inf Model; 2019 Sep; 59(9):3679-3691. PubMed ID: 31381335 [TBL] [Abstract][Full Text] [Related]
24. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification. Islam MA; Pillay TS J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527 [TBL] [Abstract][Full Text] [Related]
25. Using Hierarchical Virtual Screening To Combat Drug Resistance of the HIV-1 Protease. Li N; Ainsworth RI; Ding B; Hou T; Wang W J Chem Inf Model; 2015 Jul; 55(7):1400-12. PubMed ID: 25993532 [TBL] [Abstract][Full Text] [Related]
26. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations. Lepsík M; Kríz Z; Havlas Z Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915 [TBL] [Abstract][Full Text] [Related]
27. Toward High-Throughput Predictive Modeling of Protein Binding/Unbinding Kinetics. Chiu SH; Xie L J Chem Inf Model; 2016 Jun; 56(6):1164-74. PubMed ID: 27159844 [TBL] [Abstract][Full Text] [Related]
28. Kinetic and thermodynamic characterisation of HIV-protease inhibitors against E35D↑G↑S mutant in the South African HIV-1 subtype C protease. Maseko S; Padayachee E; Maphumulo S; Govender T; Sayed Y; Maguire G; Lin J; Naicker T; Baijnath S; Gerhardus KH J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1451-1456. PubMed ID: 31409143 [TBL] [Abstract][Full Text] [Related]
29. Structure-based design of carbon nanotubes as HIV-1 protease inhibitors: atomistic and coarse-grained simulations. Cheng Y; Li D; Ji B; Shi X; Gao H J Mol Graph Model; 2010 Sep; 29(2):171-7. PubMed ID: 20580296 [TBL] [Abstract][Full Text] [Related]
30. Determination of kinetic rate constants for the binding of inhibitors to HIV-1 protease and for the association and dissociation of active homodimer. Pargellis CA; Morelock MM; Graham ET; Kinkade P; Pav S; Lubbe K; Lamarre D; Anderson PC Biochemistry; 1994 Oct; 33(41):12527-34. PubMed ID: 7918476 [TBL] [Abstract][Full Text] [Related]
31. A Self-Adaptive Steered Molecular Dynamics Method Based on Minimization of Stretching Force Reveals the Binding Affinity of Protein-Ligand Complexes. Gu J; Li H; Wang X Molecules; 2015 Oct; 20(10):19236-51. PubMed ID: 26506335 [TBL] [Abstract][Full Text] [Related]
32. Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir. Yu Y; Wang J; Shao Q; Shi J; Zhu W Sci Rep; 2015 May; 5():10517. PubMed ID: 26012849 [TBL] [Abstract][Full Text] [Related]
33. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. Tie Y; Boross PI; Wang YF; Gaddis L; Liu F; Chen X; Tozser J; Harrison RW; Weber IT FEBS J; 2005 Oct; 272(20):5265-77. PubMed ID: 16218957 [TBL] [Abstract][Full Text] [Related]
34. Conformational analysis of TMC114, a novel HIV-1 protease inhibitor. Nivesanond K; Peeters A; Lamoen D; Van Alsenoy C J Chem Inf Model; 2008 Jan; 48(1):99-108. PubMed ID: 18173253 [TBL] [Abstract][Full Text] [Related]
35. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses. Arodola OA; Soliman ME Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167 [TBL] [Abstract][Full Text] [Related]
36. Molecular Dynamics Simulation Study of the HIV-1 Protease Inhibit ion Using Fullerene and New Fullerene Derivatives of Carbon Nanostructures. Barzegar A; Naghizadeh E; Zakariazadeh M; Azamat J Mini Rev Med Chem; 2017; 17(7):633-647. PubMed ID: 27292780 [TBL] [Abstract][Full Text] [Related]
37. Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology. Markgren PO; Lindgren MT; Gertow K; Karlsson R; Hämäläinen M; Danielson UH Anal Biochem; 2001 Apr; 291(2):207-18. PubMed ID: 11401294 [TBL] [Abstract][Full Text] [Related]
38. Energy calculations and analysis of HIV-1 protease-inhibitor crystal structures. Gustchina A; Sansom C; Prevost M; Richelle J; Wodak SY; Wlodawer A; Weber IT Protein Eng; 1994 Mar; 7(3):309-17. PubMed ID: 8177879 [TBL] [Abstract][Full Text] [Related]
39. Identifying the molecular mechanics and binding dynamics characteristics of potent inhibitors to HIV-1 protease. Li D; Liu MS; Ji B; Hwang KC; Huang Y Chem Biol Drug Des; 2012 Sep; 80(3):440-54. PubMed ID: 22621379 [TBL] [Abstract][Full Text] [Related]